Ceremuzynski L, Zaleska T, Nauman J, Nauman A, Zalewski A
Int J Clin Pharmacol Biopharm. 1979 Jun;17(6):244-9.
Metabolic effects of Metipranolol, a new beta adrenergic blocking agent, have been studied in patients with ischemic heart disease, hyperkinetic syndrome, hyperthyreosis and in healthy subjects. Administration of the drug (30 mg per day for one week) resulted in the decrease of noradrenaline excretion, blood free fatty acid level, and in lowering of blood pressure and heart rate, particularly in patients with ischemic heart disease and hyperkinetic syndrome. These alterations were accompanied by alleviation of clinical symptoms. It is suggested that Metipranolol by suppressing the activity of sympathetic nervous system and thereby diminishing lypolysis, exerts favourable clinical effects, most probably related to diminution of myocardial oxygen consumption.
新型β肾上腺素能阻滞剂美替洛尔对缺血性心脏病、运动亢进综合征、甲状腺功能亢进患者及健康受试者的代谢作用已进行了研究。给予该药（每日30毫克，持续一周）导致去甲肾上腺素排泄减少、血游离脂肪酸水平降低，以及血压和心率下降，尤其在缺血性心脏病和运动亢进综合征患者中。这些改变伴随着临床症状的缓解。提示美替洛尔通过抑制交感神经系统活性从而减少脂肪分解，发挥了有利的临床作用，很可能与心肌耗氧量减少有关。
